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dian waiting list time of 13.7 (2.5–37.8) months. The histo-
pathological examination of the explanted specimens re-
vealed a complete necrosis in 20 of 26 HCCs (76.9%), where-
as 6 (23.1%) nodules showed viable residual tumor tissue.
All transplanted patients are alive at a median time of 29.9 
months. Imaging correlation showed 100% specificity and 
66.7% sensitivity for the depiction of residual or recurrent 
tumor.  Conclusion: We conclude that TACE combined with 
RFA could provide an effective treatment to decrease the 
drop-out rate from the OLT waiting list for HCC patients. Fur-
thermore, this combination therapy results in high rates of 
complete tumor necrosis as evaluated in the histopatholog-
ical analysis of the explanted livers. Further randomized trials 
are needed to demonstrate if there is a benefit in compari-
son with a single-treatment approach. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide and is the second leading 
cause of cancer mortality worldwide  [1] . The major risk 
factor for developing HCC is chronic liver disease and 
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 Abstract 
 Purpose: To evaluate the efficiency of a multimodality ap-
proach consisting of transcatheter arterial chemoemboliza-
tion (TACE) and radiofrequency ablation (RFA) as bridging 
therapy for patients with hepatocellular carcinoma (HCC) 
awaiting orthotopic liver transplantation (OLT) and to evalu-
ate the histopathological response in explant specimens. 
 Materials and Methods: Between April 2001 and November 
2011, 36 patients with 50 HCC nodules (1.4–5.0 cm, median 
2.8 cm) on the waiting list for liver transplantation were treat-
ed by TACE and RFA. The drop-out rate during the follow-up 
period was recorded. The local efficacy was evaluated by his-
topathological examination of the explanted livers.  Results: 
During a median follow-up time of 29 (4.0–95.3) months the 
cumulative drop-out rate for the patients on the waiting list 
was 0, 2.8, 5.5, 11.0, 13.9 and 16.7% at 3, 6, 12, 24, 36 and 48 
months, respectively. 16 patients (with 26 HCC lesions) out of 
36 (44.4%) were transplanted by the end of study with a me-
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cirrhosis, which is present in 70–90% of patients  [2] . The 
major causes of cirrhosis in patients with HCC include 
hepatitis B (HBV) and hepatitis C infections (HCV), fol-
lowed by alcoholic liver disease and non-alcoholic steato-
hepatitis  [3] . Because of the widespread incidence of hep-
atitis B and C, HCC continues to increase in both the USA 
and Europe  [4] .
 Before the advent of transplantation, liver resection 
was the only method to achieve cure. However, resection 
is associated with substantial morbidity and mortality, 
and many patients do not have sufficient hepatic reserve 
to tolerate removal of enough hepatic mass to achieve 
complete tumor resection with disease-free tissue mar-
gins  [4] .
 Orthotopic liver transplantation (OLT) is an effective 
treatment for both tumor and underlying cirrhosis and
is considered the best therapeutic option in selected pa-
tients  [5] . Transplantation is unusual among therapeutic 
procedures because the need exceeds the availability and 
this therapy cannot be offered immediately. The conse-
quence of the shortage of donors and the increasing de-
mand for donor organs is an increased waiting time for 
patients listed for OLT  [6] . Out of the total number of pa-
tients with HCC on the waiting list, 20–30% have sub-
stantial disease progression while still awaiting OLT, 
leading to removal from the waiting list  [1–3] ; in order to 
reduce progression, patients are commonly considered 
for local treatment while awaiting OLT  [7] .
 In 1996, Mazzaferro et al.  [8] demonstrated that pa-
tients meeting the criteria of a single lesion  ^  5 cm or up 
to three lesions measuring  ^  3 cm each (subsequently re-
ferred to as the Milan criteria) have optimal post-OLT out-
comes with lowest rates of recurrence and overall survival 
indistinguishable from that of OLT recipients without a 
history of HCC  [8] . The limited supply of donor livers and 
the resulting long waiting list time leads to drop-out from 
candidacy due to tumor progression in a significant pro-
portion of patients who initially met surgical criteria. In-
creasing tumor burden during a long waiting time may 
also adversely affect post-OLT survival rates  [9] .
 Recent advances in interventional radiologic tech-
niques have allowed patients to be maintained within the 
Milan criteria or to be downstaged to fall within the Mi-
lan criteria  [10] in order to remain or to become eligible 
for OLT. Radiofrequency ablation (RFA) has been shown 
to be effective in a small sample of patients in the USA 
and in Europe  [11, 12] . Recently, Bruix and Sherman  [13] 
illustrated the use of intra-arterial radioembolization 
with  90 Y microspheres as a bridge to transplantation or 
resection.
 Transcatheter arterial chemoembolization (TACE), 
however, remains perhaps the most commonly used pal-
liative therapy for unresectable HCC in patients who are 
awaiting OLT as well as those who are not transplant can-
didates  [13, 14] . TACE was examined as a potentially ef-
fective downstaging modality in a recent study in Europe 
 [15] and in another study in the USA  [16] .
 In our retrospective analysis, we evaluated the effect 
of a multimodality approach consisting of TACE and 
RFA on the outcome of patients on the waiting list. Fur-
ther we evaluated the local efficacy of such a multimodal-
ity approach by analysis of histopathological results of the 
explanted livers. Evidence suggests that TACE combined 
with RFA have a synergistic effect  [17–20] in treating 
HCC and might be superior to TACE or RFA alone in 
terms on the effect of survival  [21, 22] . The decrease of 
blood flow in the HCC lesion by TACE appears to in-
crease the efficacy of RFA in destroying tumors  [23, 24] . 
Furthermore, we investigated whether the synergistic ef-
fect of this multimodality approach leads to a lower drop-
off rate of HCC patients from the OLT waiting list and to 
a higher rate of complete necrosis in the treated HCC 
nodules.
 Material and Methods 
 Patients 
 Between April 2001 and November 2011, 44 patients with 
HCC were first listed for liver transplantation. Of the 44 patients, 
8 did not have a complete follow-up and were excluded from the 
study. The remaining 36 patients (29 men, 7 women; aged 42–71 
(mean 59.2) years) were treated with a multimodality treatment 
approach (TACE followed by RFA) before OLT. 26 patients had 
solitary HCC, 6 patients had two nodules and 4 patients had three 
nodules. All patients fulfilled the Milan criteria prior to the first 
combined therapy. 34 patients presented with Child-Pugh A cir-
rhosis and 2 patients with Child-Pugh B cirrhosis.
 According to the Barcelona Clinic Liver Cancer (BCLC) stag-
ing and treatment algorithm, 34 patients presented with early-
stage HCC (BCLC stage A) while 2 patients were stratified as 
BCLC stage 0 patients (very-early-stage HCC). The reason for a 
locoregional therapy instead of a surgical resection for the 2 pa-
tients with resectable HCCs was that the patients refused to un-
dergo surgery or lesion location deemed unfeasible for surgical 
resection. The diagnosis of HCC was confirmed by imaging tech-
niques according to the European Association for Study of the 
Liver consensus conference criteria. In 3 patients a biopsy was 
necessary due to vague imaging findings.
 The total number of HCCs in all patients was 50 with a maxi-
mum diameter that varied from 1.4 to 5.0 cm (mean 2.8  8 0.6, 
median 2.6). Written informed consent was obtained from all pa-
tients before treatment.
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 The cause of liver cirrhosis was: HCV infection in 20 patients, 
HBV infection in 5 patients, alcohol-induced cirrhosis in 7 pa-
tients, and cryptogenic in 4 patients. The decision to implement 
neoadjuvant therapy was made in a multidisciplinary liver tumor 
management conference attended by transplant surgeons, surgi-
cal oncologists, hepatologists, radiologists and liver pathologists. 
Patients listed for OLT with at least one HCC nodule  1 2 cm and 
an anticipated waiting time of more than 3 months were consid-
ered for neoadjuvant therapy. Two patients with HCC nodules
 ! 2 cm refused surgical therapy prior to transplantation.
 Patients were referred for transplant evaluation if they were 
not resectable but met the Milan criteria. Patients who fulfilled 
the transplant criteria were treated with the intent to bridge them 
to transplantation. At our institution the following algorithm for 
the treatment selection was usually respected: if the lesion was 
between 2 and 5 cm or if patients had more than one lesion, the 
patient had TACE followed by RFA. During the previously men-
tioned period, 36 patients were referred to a combined therapy 
consisting of TACE followed by RFA.
 A prerequisite for locoregional treatment was a sufficient 
blood clotting status with a partial thromboplastin time  ! 40 s, 
INR  ! 1.75, and a platelet count  1 40,000/mm 3 . As part of the pre-
treatment work-up, CT examinations with a multiphasic protocol 
(contrast flow rate 5 ml/s (unenhanced, arterial, portal-venous 
and late phases)) were performed in each patient using multide-
tector scanners. In addition, prior to the tumor management con-
ference, a contrast medium-enhanced MRI examination was per-
formed in all patients ( fig. 1 a, b,  2 a).
 Conventional Transcatheter Arterial Chemoembolization 
 Prior to RFA a conventional Lipiodol-based (max. 10 ml) 
TACE with a chemotherapeutic drug (epirubicin hydrochloride) 
was performed in each patient. Calibrated microspheres (diame-
ter 250   m) were added in those patients where the Lipiodol did 
not devascularize the HCC nodule completely. Angiography was 
performed by way of a transfemoral approach in all patients.
 After superselective catheterization of the hepatic and tumor-
feeding arteries, an emulsion consisting of 50 mg epirubicin hy-
drochloride (Farmorubicin  ; Pfizer Pharma) and max. 5 ml io-
dized oil (Lipiodol  Ultra-Fluid; Guerbet) were slowly infused 
under fluoroscopic guidance until stasis within the HCC lesion or 
the tumor-feeding vessel was reached. Calibrated polyvinyl alco-
hol particles (Bead Block  ; Biocompatibles International, Farn-
ham, UK) or other microspheres (Embozene  ; Celonova Biosci-
ences, Atlanta, Ga., USA) were applied to achieve complete stasis 
in the tumor if necessary. Patients were carefully observed during 
the entire procedure, and analgesics and antiemetics were admin-
istered on demand.
 Radiofrequency Ablation 
 A more detailed description of the RFA procedures at our in-
stitution is depicted elsewhere  [25] . After multiphase contrast-
enhanced computed tomography (CT) was performed, the opti-
mal electrode pathway to the HCC lesion was determined. In cas-
es of HCC nodules with critical anatomical locations or lesions 
that are not amenable to US, a CT-fluoroscopy guidance was per-
formed. The exact positioning of the electrode and the complete 
coverage of the lesion with the hooks fully distended was war-
ranted by CT-/CT-fluoroscopy guidance ( fig. 2 b), or when there 
was doubt, with additional contrast-enhanced CT scans. For 
HCCs  ! 3 cm in size, a single session of ablation with a maximum 
electrode diameter of 5 cm was used to provide a sufficient safety 
margin. In larger lesions, the electrode was repositioned several 
times in a single session in order to achieve a volume large enough 
to cover the entire HCC including a safety margin. To reduce the 
risk of puncture-related bleeding, electrode-track ablation was 
performed after completion of the procedure at a reduced power 
level. Our standard approach for RFA was to perform the proce-
dure under moderate sedation and local anesthesia. The majority 
of ablations were performed with administration of a combina-
tion of midazolam maleate, parecoxib sodium and piritramide. 
Blood pressure, heart rate and oxygen saturation were monitored 
continuously. In patients who presented with low tolerance to 
pain, or lesions that were difficult to target, the procedure was 
performed under general anesthesia. Preinterventional antibiot-
ics were used for all patients.
 Liver Transplantation 
 According to the Eurotransplant indication guidelines for liv-
er transplantation to treat HCC, all patients revealed a disease 
pattern within the Milan criteria at the beginning of their treat-
ment. In general, liver transplantations were carried out using a 
‘piggyback’ technique with preservation of the vena cava as a clas-
sic piggyback technique (either end-to-side or side-to-side cavo-
cavostomy), as this represents our center’s standard. Solely in se-
lected cases, according to anatomic prerequisites and the subjec-
tive considerations of the surgeon, a vena cava resection was 
performed with subsequent in situ transplantation of the graft. 
Arterial reconstruction was intended as anastomosis between the 
donor and recipient junctions of the hepatic and gastroduodenal 
artery. Other arterial reconstructions represented rare excep-
tions.
 Follow-Up 
 The efficacy of the therapy was determined using contrast-
enhanced CT or MR scans obtained 6–8 weeks ( fig. 1 c, d,  2 c) and 
then every 3 months after combined locoregional therapy. In the 
16 transplanted patients the follow-up was performed by contrast 
medium-enhanced (Gd-EOB-DTPA disodium (Primovist)/Feru-
carbotran (Resovist, until 2007)) MRI examinations. The MRI 
examinations were conducted in high-field scanners (Magnetom 
Sonata  (1.5 T), Magnetom Avanto  (1.5 T) and Magnetom 
Verio  (3 T), Siemens  , Forchheim, Germany) and were, among 
others, composed of a dynamic phase and an accumulation phase. 
The treatment sessions were repeated if viable tumor tissue was 
depicted during the follow-up.
 Pathological Examination of the Explant Specimens 
 Each explanted liver was carefully examined by two patholo-
gists for number of tumor nodules and percentage of tumor ne-
crosis. The explanted livers were serially sectioned and the num-
ber, diameter and location of neoplastic nodules were recorded. 
All hematoxylin and eosin (HE)-stained sections taken at the 
time of processing were evaluated. The percentage of tumor ne-
crosis was assessed in each tumor nodule based on these sections, 
which in some cases did not represent the entire tumor.
 Statistical Analysis 
 Descriptive statistics are provided as mean  8 SD for continu-
ous variables and absolute and relative frequencies for categorical 
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 Fig. 1. Images of a 57-year-old man with hepatitis C-induced cir-
rhosis and multifocal HCC. Contrast medium-enhanced MRI of 
a HCC nodule in segment VIII prior to the locoregional therapy 
in the arterial phase ( a ) and in the accumulation phase ( b ). Axial 
CT view of the arterial phase 6 weeks after TACE/RFA ( c ) with 
residual viable tumor (arrow) proximal to the ablation area ( d ).
 e 6 months after the first locoregional therapy a histological slice 
(HE stain) of a lesion in segment VIII shows a largely necrotic 
area. f In the higher magnification bordering regions of viable-
appearing tumor to the right are shown. 
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 Fig. 2. Images of a 42-year-old woman with hepatitis C and mul-
tifocal HCC.  a Contrast-enhanced axial MRI view in the arterial 
phase reveals a HCC nodule in liver segment VI.  b During the 
RFA procedure with RFA needle in the HCC nodule.  c Contrast-
enhanced transverse CT image (arterial phase) obtained 6 weeks 
after locoregional therapy showing an ablation area with central 
Lipiodol storage (arrow) and without any visible viable and con-
trast-enhancing tumor tissue. Histological slices (HE stain) 12 
months after locoregional therapy demonstrate complete necrosis 
of the HCC nodule with coagulative necrosis surrounded by fi-
brous pseudocapsula ( d ) and histiocytic reactions in the periph-
ery ( e ).  f The highest magnification depicts preservation of hepa-
tocyte architecture with homogeneous hypereosinophilic cyto-
plasm and loss of normal nuclear elements. 
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variables. Conventional measures of diagnostic accuracy (sensi-
tivity, specificity, positive and negative predictive value (PPV and 
NPV, respectively)) were derived using histology as the gold stan-
dard. Associated 95% confidence intervals (CI) were calculated 
using the binominal distribution. Finally, survival curves and 
median survival as well as pertaining 95% CI were estimated by 
the Kaplan-Meier method and group comparisons were made by 
log-rank test statistics. All analyses were performed by SAS ver-
sion 9.2 (SAS Institute, Inc., Cary, N.C., USA) and a two-sided p 
value of 0.05 was considered to indicate statistical significance.
 Results 
 Thirty-six patients underwent combined neoadjuvant 
therapy consisting of TACE before RFA while on the 
waiting list for liver transplantation. The majority of sub-
jects were men (80.5%), the mean age of all patients was 
58 years ( 8 6.7, median 59.2). All patients received multi-
modality HCC treatment with a mean of 2.0  8 1.6 pro-
cedures per patient. Five out of the 16 transplanted pa-
tients received more TACE treatment sessions than RFA 
treatment sessions, as shown in  table 1 . All these patients 
have had only TACE therapies prior to the combined 
therapy.
 The treatment sessions were repeated in 4 patients due 
to the recurrence of HCC, depicted by MRI scans during 
the follow-up. According to the SIR guidelines  [26] , no 
major complications were observed. The most common 
postprocedure morbidity was postembolization syn-
drome, consisting of fatigue, mild nausea, low-grade fe-
ver, and abdominal pain that was easily managed with 
oral analgesics and antiemetics. In 8% of the cases there 
was slight subcapsular bleeding after RFA with neither 
clinical symptoms nor progression in an additional CT 
scan performed the day after RFA. Between diagnosis of 
HCC and the first treatment there was a median time in-
terval of 37.5 days (range 3–1,433, mean 108.4  8 109.4.1). 
The median time interval between TACE and RFA was 1 
day (range 0–20, mean 3.2  8 2.7). The median time on 
the waiting list was 27.4 months (range 4.0–95.3, mean 29 
 8 16.6). 16 of the 36 (44.4%) patients were transplanted 
until the end of the study (November 2011).
 Transplanted patients showed a median time of 11.3 
months (range 4.6–33.8, mean 13.5  8 6.5) between the 
time of the initial diagnosis and date of transplantation 
( table 2 ). Without the transplanted patients the median 
time on the waiting list was 37.8 months (range 6.1–95.3, 
mean 40.5  8 14.9). There were 2 cases of HCC and cir-
rhosis-related deaths among the listed patients 29 and 36 
months after initial diagnosis. Four patients were listed 
and removed (drop-out) from the transplant waiting list 
at 6, 16, 22 and 46 months, respectively, due to tumor pro-
gression. Two patients died after 6.5 and 30 months of 
waiting time on the list because of liver failure. The in-
tention-to treat drop-out rate was 0, 2.8, 5.5, 11.0, 13.9 and 
16.7% at 3, 6, 12, 24, 36 and 48 months, respectively. A 
Table 1. C haracteristics of the transplanted patients
Pa-
tient
Age/
sex
Nod-
ules
n
Waiting 
time
months
TACE
n
RFA
n
Tumor
size
cm
Necro-
sis
%
TNM 
stage
1 47/M 1 6.3 3 1 2.5 100 2
2 50/M 3 8.3 4 1 3.8 90 2
3.4 100
1.6 100
3 57/M 2 24.5 1 1 2.5 100 2
2.0 75
4 60/M 2 9.0 1 1 3.5 100 2
1.7 100
5 58/M 3 19.3 2 2 3.6 85 2
2.7 100
1.9 100
6 49/M 1 5.2 1 1 3.7 100 2
7 62/M 1 22.2 1 1 1.9 100 1
8 51/M 1 4.6 1 1 1.6 90 1
9 48/M 1 11.0 1 1 2.8 80 2
10 57/M 2 7.34 1 1 2.8 100 2
1.4 100
11 42/F 2 11.5 2 2 1.6 100 2
1.5 100
12 54/M 1 33.7 5 2 2.3 100 2
13 63/M 1 13.2 1 1 1.7 100 1
14 55/F 2 18.3 3 1 3.2 100 2
1.6 100
15 57/M 1 7.3 4 2 2.8 80 2
16 58/M 2 15.2 1 1 2.7 100 2
2.7 100
Table 2. C omparison of the last imaging procedure in the follow-
up with histologic findings
Imaging findings H istologic findings
positive negative total
Positive 4 0 4
Negative 2 20 22
Total 6 20 26
 Ashoori et al. Digestion 2012;86:338–348344
detailed characterization of the drop-out patients is dis-
played in  table 3 . The mean age of the drop-out patients 
is 64.5 ( 8 5.67) years and is above the mean age (58.79  8 
6.43 years) of the follow-up patients.
 The other parameters (Child-Pugh and BCLC) failed 
to show any significant differences. The drop-out pa-
tients showed a median time on the waiting list of 19 
months (mean 20.92  8 11.75). This is even below the av-
erage of the follow-up patients (see above). 16 patients re-
ceived full-size OLT and the transplantation was per-
formed according to standardized procedures. Due to a 
chronic rejection reaction in 1 case a retransplantation 
was required after 11 months which was performed suc-
cessfully. The remaining transplanted patients experi-
enced an uneventful postoperative period. All trans-
planted patients were alive at a median time of 29.9 
months (range 10.6–62.9, mean 35.6  8 11.6) after OLT 
and there was no evidence of recurrent HCC at follow-up.
 Histological Findings in the Explant Specimens 
( table 1 ) 
 In concordance with the imaging studies during fol-
low-up 26 nodules were found in the 16 explanted livers. 
The diameter ranged between 1.4 and 3.8 cm with a me-
dian of 2.5 cm (mean 2.4  8 0.65 cm). Two pathologists 
performed an independent review of the histological 
slides of the HCC nodules in the explants. All nodules 
had been treated by at least one session TACE and one 
session RFA ( table 1 ).
 Of 26 nodules, 20 (76.9%, mean diameter 2.3 cm) dem-
onstrated complete necrosis ( fig. 2 e, f), whereas 6 (23.1%, 
mean diameter 2.8 cm) nodules showed viable residual 
tumor tissue ( fig.  1 e, f). Coagulative-type necrosis was 
seen in all cases. In nodules showing partial necrosis the 
non-necrotic portion of the tumor was located peripher-
ally, with the central area showing complete necrosis. The 
portion of viable tumor tissue was estimated by the pa-
thologist and ranged between 5 and 25% of the whole le-
sion.
 Correlation between the Last Follow-Up MRI 
Examination of the Transplanted Patients and the 
Pathological Outcome 
 The mean interval between the last imaging procedure 
and transplantation was 1.3 months. All patients under-
went gadolinium-enhanced MRI. A positive result in the 
imaging procedure was moderately sensitive for the de-
tection of residual or recurrent tumor as determined by 
histology (sensitivity 66.7%, 95% CI 22.2–95.7) but cor-
rectly ruled out the presence of viable tumor in all cases 
(specificity 100%, 95% CI 83.0–100). Thus, while the pos-
itive imaging finding was excellent in predicting the pres-
ence of viable tumor (PPV 100%, 95% CI 40.0–100), the 
NPV was high (90.9%, 95% CI 70.8–99.0) due to the low 
prevalence of disease (23%).
 Analysis of the Survival Data of the Non-Transplanted 
Patients 
 There was a trend towards longer survival in subjects 
with complete remission but no statistically significant 
difference as compared to subjects with partial response 
(residual or recurrent tumor) on baseline imaging, cer-
tainly attributable to sample size (mean survival in sub-
jects with partial response: 27.4 months, 95% CI 21.2–33.6 
months;  fig. 3 a). There was also no significant difference 
between the survival of transplanted patients (mean 40.5 
months, 95% CI 38–43) compared with non-transplant-
ed patients (30.4 months, 95% CI 29.1–31.7;  fig. 3 b).
 Discussion 
 Liver transplantation has become a widely accepted 
therapy for HCC patients with tumor burdens within 
guidelines, generally either the Milan or University of 
California, San Francisco, criteria. Transplantation is the 
only treatment option that cures both the HCC and the 
underlying cirrhosis. It is especially efficient in early-
stage HCCs, which has been demonstrated in various 
studies  [8, 27, 28] . Despite these results, transplantation 
is unusual among therapeutic procedures as the need ex-
ceeds availability of transplant organs and therefore OLT 
cannot be provided immediately when HCC is diag-
nosed. The shortage of organs results in a waiting time in 
which the phenotype of the disease may change with a 
Table 3. B aseline characteristics of the drop-out patients
Pa-
tient
Gender Age Child-
Pugh
BCLC Time on waiting
list, months
Cause
1 M 65 A A  6.0 T
2 M 51 B A  6.5 D
3 M 68 A A 22 T
4 M 57 B A 30 D
5 M 70 A A 16 T
6 M 64 A A 46 T
T = Tumor progression; D = death.
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possible drop-out from the waiting list. The incidence of 
disease progression while listed for organ replacement is 
10–23%  [29, 30] .
 Data from single-center experiences and Markov 
model analyses  [9, 31] set the risk of tumor progression
at 3 months at 8 and 15% for very-early-stage and early-
stage HCC, respectively. Comparing this to our results 
with no patient showing progressive disease at 3 months 
but 4 patients showing progressive tumor burden at a lat-
er point during follow-up, it appears that the use of a mul-
timodality treatment approach provides a benefit for the 
patients. According to United Network of Organ Sharing 
data  [32] the drop-out rate for patients with HCC in cir-
rhosis on the waiting list is 8.7, 16.9, and 31.8% at 3, 6 and 
12 months, respectively. These numbers are substantially 
higher compared to the favorable results we can report 
from our retrospective analysis with a drop-out rate of 0, 
2.8 and 5.5% after 3, 6 and 12 months, respectively. This 
represents a strong indication that multimodality treat-
ment for HCC is an effective tool for bridging patients 
awaiting transplantation.
 Freeman et al.  [32] demonstrated that in case of HCC 
the drop-out rate is higher compared to the drop-out rate 
observed for non-malignant diseases, which again sup-
ports the utilization of locoregional therapies to decrease 
the drop-out rate by preventing progression of disease. 
The efficacy of locoregional therapy has been shown in 
previous studies. In conformity with this, the American 
Association for the Study of the Liver practice guidelines 
 [13] state that local ablation is a safe and effective therapy 
for patients who cannot undergo resection, or as a bridge 
to transplantation. Lu et al.  [11] reported the outcome of 
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 Fig. 3.  a Survival by imaging response.
 b Survival of transplanted patients com-
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52 consecutive patients accepted for OLT and treated 
with percutaneous RFA and revealed a drop-out rate of 
5.8% after 12 months while on the waiting list. This re-
ported drop-out rate matches our drop-out rate of 5.5% 
after 12 months in a patient cohort of the same size we are 
reporting on in the analysis. This illustrates that these 
published drop-out rates are reproducible among various 
centers using locoregional therapies for bridging.
 Other studies with RFA as a single modality therapy 
prior to OLT vary in their results. In a prospective study 
with 50 consecutive patients treated with RFA prior to 
OLT, Mazzaferro et al.  [12] reported a drop-out rate of 0% 
after a mean waiting time of 9.5 months. This is superior 
to the results in our study, although the patient popu-
lation in both studies is similar. On the other hand, in 
another study from 2002 by Fontana et al.  [33] there is a 
drop-out rate of 21% during a mean waiting time of 7.9 
months among 33 patients treated with RFA prior to OLT.
 In another prospective study, Cillo et al.  [34] analyzed 
the drop-out probability of 100 listed patients treated with 
locoregional therapy prior to liver transplantation and re-
vealed a drop-out rate of 6, 11 and 25% at 6, 12 and 24 
months, respectively. These values are higher than report-
ed in our study, most likely because of a bias in the selec-
tion criteria. Our analysis also included 4 very-early-stage 
HCC patients according to the BCLC criteria, which might 
have an impact on our results. A further study by Cillo et 
al. [34] contained 40 patients, which exceeded the Milan 
criteria; however, in our study all included patients met the 
Milan criteria. In another study, Maddala et al.  [35] re-
vealed in 54 listed HCC patients who underwent chemo-
embolization prior to OLT a drop-out rate of 15 and 25% 
at 6 and 12 months, respectively. These results are inferior 
to our results, indicating that the combined use of TACE 
and RFA provides additive benefit to the patients.
 Most studies that assessed the benefit of RFA pre-OLT 
 [11, 12, 16, 28, 33, 36] demonstrated a decrease in the 
drop-out rate compared with untreated HCC patients 
 [32] , whereas a meta-analysis by Lesurtel et al.  [37] as-
sessed the impact of TACE as a neoadjuvant therapy pri-
or to OLT for HCC. They demonstrated no sufficient ev-
idence of benefits when TACE is used before transplanta-
tion. Experiences with combined therapies such as TACE 
followed by RFA  [24, 25, 38, 39] resulted in a higher local 
tumor control rate due to the higher rates of complete tu-
mor necrosis. This is also in line with our results of the 
histopathological evaluation of the HCC nodules of liver 
explants. Our histopathological evaluation depicted a 
high rate of complete necrosis in 75% of the 24 nodules. 
Lu et al.  [11] measured the effectiveness of RFA in HCCs 
on the basis of histological findings in 24 explanted livers 
and obtained a complete necrosis rate of 74% to similar 
results. Marin et al.  [40] measured the local efficacy of 
various interventional neoadjuvant treatment methods 
in explanted livers and found a complete necrosis rate of 
only 10%. Although complete tumor necrosis is desirable, 
also an incomplete tumor necrosis is able to reduce the 
size of the tumor and may confine disease progression 
and thereby improve outcome, particularly in patients 
awaiting liver transplantation. In any case, a standard-
ized histopathological analysis is needed to compare the 
local efficacy of a single-treatment approach to multimo-
dality treatment consisting of TACE and RFA.
 In this context, the question arises how TACE and 
RFA should be sequenced. The advantage of TACE prior 
to RFA is the reduced heat sink effect with the ability to 
create larger ablation zones more easily. The advantage of 
using TACE after RFA is that RFA generates a hyperemic 
rim surrounding the ablation area, which then can con-
sequently be targeted by transarterial means more effec-
tively. Further studies need to clarify how locoregional 
treatment options should be implemented in the treat-
ment paradigm of non-resectable HCC.
 With drop-out rates of 0, 2.8, 5.5, 11.0, 13.9 and 16.7% 
after 3, 6, 12, 24, 36 and 48 months, respectively, as re-
ported in our analysis, there appears to be a clear decrease 
of drop-out rates compared with untreated HCC nodules 
 [32] and to many previously discussed results of studies 
with RFA and especially TACE as the sole bridging treat-
ment  [11, 34, 35] . Especially in the studies with RFA as the 
single-treatment method there is a high variation among 
different studies, as mentioned above, and it remains un-
clear if there is a significant benefit of a multimodality 
approach in comparison to RFA alone.
 Our results warrant randomized prospective studies 
to compare the multimodality treatment versus single 
modality approach. Moreover, standardized histopatho-
logical analysis would also contribute to a more repro-
ducible assessment of the local efficacy of various applied 
treatment methods. Finally, in concordance with the 
study by Lu et al.  [11] , imaging correlation showed 100% 
specificity for the detection for residual or recurrent tu-
mor. On the other hand, a positive result in the imaging 
procedure was with 66.7% moderately sensitive for the 
detection of residual or recurrent tumor. This sensitivity 
was higher than that obtained by Lu et al. (sensitivity 
36%) which could be attributed to the different imaging 
modalities used in the follow-up.
 In our study all transplanted patients were examined 
by gadolinium-enhanced MRI, whereas in the study by 
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Lu et al.  [11] almost 96% of the patients were examined by 
contrast-enhanced CT. Dromain et al.  [41] showed al-
ready in a study from 2002 that MRI has an edge over CT 
in detecting viable HCC tumors after being treated with 
RFA. An analysis of the survival of the non-transplanted 
patients depicted a trend toward longer survival in pa-
tients with complete remission on imaging. There is also 
a trend toward longer survival of transplanted patients 
compared with non-transplanted patients. Both analyses 
failed to reach statistical significance, which could be at-
tributed to the small patient population. These tendencies 
should be confirmed by performing further studies with 
a higher number of subjects.
 There are various limitations as our study is a retro-
spective single-center study and as in comparison to most 
other studies there is a selection bias towards patients 
with a lower tumor burden in our study. Further, it should 
be considered that this study includes a small number of 
patients (36 investigated and 16 transplanted).
 Conclusion 
 In this retrospective study we could show that the mul-
timodality approach of RFA following TACE in HCC pa-
tients awaiting liver transplantation might be effective in 
decreasing the drop-out rate from the waiting list. More-
over, this combined therapy results in high rates of tumor 
necrosis as evaluated in the histopathological analysis of 
the explanted livers. These promising pathological find-
ings warrant further prospective randomized trials – in-
cluding multiple transplantation centers – to confirm if 
there is a benefit of a multimodality approach in com-
parison to a single-treatment approach in bridging pa-
tients on a waiting list.
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